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Background: The authors investigated the hypothesis that isoflurane 
modulates nitric oxide (NO) synthesis and protection against myocardial 
infarction through time-dependent changes in expression of key NO re-
gulatory proteins, guanosine triphosphate cyclohydrolase (GTPCH)-1, the 
rate-limiting enzyme involved in the biosynthesis of tetrahydrobiopterin 
and endothelial nitric oxide synthase (eNOS) .
Methods: Myocardial infarct size, NO production (ozone-mediated chemi-
luminescence), GTPCH-1, and eNOS expression (real-time reverse trans-
criptase polymerase chain reaction and western blotting) were measured 
in male Wistar rats with or without anesthetic preconditioning (APC; 1 .0 
minimum alveolar concentration isoflurane for 30 min) and in the presence 
or absence of an inhibitor of GTPCH-1, 2,4-diamino-6-hydroxypyrimidine .
Results: NO−2 production (158 ± 16 and 150 ± 13 pmol/mg protein at ba-
seline in control and APC groups, respectively) was significantly (P < 0 .05) 
increased 1 .5 ± 0 .1 and 1 .4 ± 0 .1 fold by APC (n = 4) at 60 and 90 min of re-
perfusion, respectively, concomitantly, with increased expression of GTP-
CH-1 (1 .3 ± 0 .3 fold; n = 5) and eNOS (1 .3 ± 0 .2 fold; n = 5) . In contrast, 
total NO (NO−2 and NO
−
3) was decreased after reperfusion in control expe-
riments . Myocardial infarct size was decreased (43 ± 2% of the area at risk 
for infarction; n = 6) by APC compared with control experiments (57 ± 1%; 
n = 6) . 2, 4-Diamino-6-hydroxypyrimidine decreased total NO production 
at baseline (221 ± 25 and 175 ± 31 pmol/mg protein at baseline in control 
and APC groups, respectively), abolished isoflurane-induced increases in 
NO at reperfusion, and prevented reductions of myocardial infarct size by 
APC (60 ± 2%; n = 6) .
Conclusion: APC favorably modulated a NO biosynthetic pathway by 
up-regulating GTPCH-1 and eNOS, and this action contributed to prote-
ction of myocardium against ischemia and reperfusion injury . 
A GROWING body of evidence implicates endothelial nitric oxide synthase 
(eNOS)–derived nitric oxide (NO) as a critical mediator of anesthetic pre-
conditioning (APC)1 and also suggests that an NO biosynthetic path-way 
is importantly modulated by disease states .2  Three distinct nitric oxide 
synthase (NOS) isoforms, neuronal NOS (nNOS), inducible NOS (iNOS), 
and eNOS, contribute to NO production in the heart3 ; however, eNOS, but 
not nNOS or iNOS, seems to play a major role during APC .1,4 We previo-
usly demonstrated that the trigger and mediator phases of delayed pre-
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conditioning with isoflurane were blocked by the nonselective NOS inhibi-
tor, l-NG- nitroarginine methyl ester, whereas selective inhibitors of nNOS 
or iNOS had no effect .4  Isoflurane increases the phosphorylation of serine 
1177 on eNOS and stimulates NO production in human coronary artery 
endothelial cells and preconditions myocardium against infarction through 
an eNOS-sensitive pathway .1 However, the precise mechanisms whereby 
isoflurane modulates NO biosynthesis are incompletely understood . eNOS 
activity is regulated by intracellular localization, posttranslational modifica-
tions, protein–protein interactions, and tetra-hydrobiopterin (BH4) cofactor 
availability .2 The current investigation examined the hypothesis that iso-
flurane protects myocardium against ischemia and reperfusion injury by a 
time-dependent modulation of NO biosynthetic pathway gene and protein 
expression .
Materials and Methods
All experimental procedures and protocols used in this investigation were 
reviewed and approved by the Institutional Animal Care and Use Com-
mittee of the Medical College of Wisconsin, Milwaukee, Wisconsin. Furt-
hermore, all conformed to the Guiding Principles in the Care and Use of 
Animals of the American Physiologic Society and were in accordance with 
the Guide for the Care and Use of Laboratory Animals (2011) .
In vivo Myocardial Infarction Model
Adult male Wistar rats (n = 254; 8 to 12 weeks old), weighing 300 to 360 g 
were anesthetized with thiobutabarbital sodium (100 mg/kg, intraperitone-
al) and instrumented for the measurement of systemic hemodynamics as 
described previously .5 Briefly, heparin- filled catheters were inserted into 
the right jugular vein and the right carotid artery for fluid administration 
and measurement of arterial blood pressure, respectively . A tracheotomy 
was performed, and rats were ventilated with positive pressure ventilation 
using an air and oxygen mixture . A left thoracotomy was performed in the 
fifth intercostal space, and the pericardium was opened . A 6-0 prolene 
ligature was placed around the proximal left anterior descending coronary 
artery and vein in the area immediately below the left atrial appendage for 
the production of coronary artery occlusion and reperfusion .
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The experimental protocol is illustrated in figure 1. Following instrumentati-
on and after 30 min of stabilization, rats were randomly assigned to 30-min 
preconditioning with isoflurane (1 .3%; 1 minimum alveolar concentration) 
followed by washout for 15 min, or no treatment with volatile agent (con-
trol group), and in the presence or absence of an inhibitor of guanosine 
triphosphate cyclohydrolase (GTPCH)-1, 2,4-diamino-6-hydroxypy-rimi-
dine (DAHP; 200 mg/kg, intraperitoneal) in separate experimental groups . 
Myocardial infarct size was measured by triphenyltetrazolium chloride sta-
ining and expressed as a percentage of the area at risk (AAR) for infarction 
as described previously . 5 In additional groups of rats, left ventricular (LV) 
tissue samples were collected at the following time points: before coro-
nary artery occlusion; immediately before reperfusion; and after 30, 60, 
and 90 min of reperfusion .
Fig. 1.  Schematic diagram depicting the experimental protocols used to determine 
myocardial infarct size and modulation of nitric oxide in rats in vivo . 
APC = anesthetic preconditioning; DAHP = 2,4-diamino-6-hydroxypyrimidine; LV = left ven-
tricle; MAC = minimum alveolar concentration; OCC = coronary artery occlusion.
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Tissue NO−2 and NOx Analysis




3) concentrations from LV samples 
were quantified by ozone-mediated chemiluminescence . Tissue samples 
were rinsed, snap frozen in liquid nitrogen, pulverized and homogenized 
in buffer containing (150 mM NaCl, 20 mM Tris,1 mM EDTA,1 mM EGTA,1% 
Triton v/v, pH 7 .5) followed by homogenization . Homogenates were cen-
trifuged, and 250 μg of supernatant was filtered (Amicon® Ultra Centri-
fugal Filter, 10,000 MWCO, Millipore Corporation, USA) by centrifugation 
for 30 min at 12,000 rpm and 4°C (Microfuge R 22R Centrifuge, Beckman 
Coulter, USA). Samples (30 μl) were refluxed in reaction solution (50 mg 
KI in 1 ml of double-distilled water) mixed with glacial acetic acid (4 ml), 
and NO−2 was quantified by a chemiluminescence detector (Sievers 280 
model NO analyzer, GE Analytical Instruments, USA) as described previo-
usly .6 For NOx measurement, a 20-μl sample was injected into the reaction 
chamber of the NO analyzer containing a heated (95°C) solution of vana-
dium chloride and hydrochloric acid, which reduces NO−2 and NO
−
3 to NO, 
as described previously .7 Each sample was analyzed in triplicate . NO−2 
and NOx concentrations were calculated after subtraction of background 
levels and normalized to protein content (Bradford method) .
eNOS and GTPCH-1 Expression
Gene expression in LV samples was quantified by real-time reverse trans-
cription polymerase chain reaction (RT-PCR) at five selected time points . 
Tissue was homogenized using a TissueLyser LT (Qiagen, USA) . Total 
RNA was isolated using RNeasy Mini Kit (Qiagen) and treated with RNA-
se-free DNAse (Qiagen) to remove residual DNA contamination . The qu-
ality and quantity of RNA was determined by UV-vis spectrophotometry 
(NanoDrop® ND-1000, Nano-Drop Technologies, USA). Only samples with 
260/280-nm absorbance ratios between 1 .8 and 2 were used for further 
analysis . Immediately after the quality control assessment, reverse trans-
cription of total RNA samples to cDNA was performed using iScript cDNA 
synthesis Kit (Bio-Rad, USA) . RT-PCR was performed using SYBR Green 
chemistry (iQ SYBR Green Supermix; Bio-Rad) and analyzed by an iCycler 
iQ5 (Bio-Rad) . The reaction conditions consisted of initial template dena-
turation at 95°C for 3 min, followed by 35 cycles of amplification (95°C 
for 10 s and 60°C for 30s) . Amplification was followed by a melting curve 
analysis, ranging from 55° to 95°C, with increasing steps of 0 .5°C every 10 
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s . Expression of mRNA levels was normalized to β-glucuronidase . Sam-
ples were run in duplicate. The RT-PCR reaction was performed in a 25-μl 
reaction volume . A single PCR master mix was used for each set of sam-
ples to minimize errors. Integrated DNA Technologies (USA) primers (0.5 μl 
forward and 0.5 μl reverse primers) were used; 12.5 μl of iQ SYBR Green 
(Bio-Rad), 9.5 μl of nuclease-free water, and 2 μl of cDNA samples were 
added . The primers used are shown in table 1 .
Table 1.  RT-PCR Primers
Forward Reverse
GTPCH-1 TGC TTA CTG GTC CAT TCT G TCC TTC ACA ATC ACC ATC TC
eNOS AGC CCG GGA CTT CAT CAA TCA G GCC CCA AAC ACC AGC TCA 
CTC TC
β-Glucuronidase GTG GGG ATA ATG ACT TGCA G GGA ACC CCT GGT AGA ACA GT
eNOS = endothelial nitric oxide synthase; GTPCH-1 = guanosine triphosphate cyclohydro-
lase 1; RT-PCR = reverse transcription polymerase chain reaction.
Comparative cycle threshold (Ct) method for RT-PCR data analysis was 
used to calculate the relative change in expression of the target gene: the 
Ct values of the replicates were averaged and adjusted for the β-glucu-
ronidase by taking the difference in Ct (∆Ct) . The difference in expression 
between the APC and control groups for each gene and each time point 
was calculated (∆∆Ct between groups), as well as comparing the values 
of the occlusion and reperfusion time points to pre-occlusion within each 
group and gene (∆∆ Ct within group) .
GTPCH- 1 and eNOS protein expression levels in LV samples were exami-
ned by western blot analysis. Briefly, 100 μg of tissue proteins were loaded 
onto a Criterion Precast Gel (10% Tris-HCl, Bio-Rad), and proteins were 
separated by electrophoresis . The separated proteins were transferred 
overnight to a polyvinylidene fluoride membrane, and the membrane was 
blocked with 5% bovine serum albumin (Sigma-Aldrich, USA) containing 
5% nonfat dry milk . The blots were then incubated with primary antibody 
against GTPCH-1 (the antibody was kindly provided by Gregory Kapatos, 
Ph .D ., Wayne State University Medical School, Detroit, Michigan) prepa-
red with 5% milk in Tris-buffered saline and Tween 20 (TBS-T) at 1:1000 
dilution . The blots were washed five times with 5-min rinse intervals with 
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TBS-T (0 .1%) and then incubated with the secondary antibody (goat anti 
rat, IgG -HRP, Santa Cruz Biotechnology, USA) prepared in 5% milk in 
TBS-T in 1:5000 dilution. For eNOS identification, the blots were incuba-
ted with primary antibody against eNOS (Santa Cruz, sc-654) prepared in 
3% bovine serum albumin in TBS-T at 1:1000 dilution, and after wash, the 
blots were incubated with the secondary antibody (GE Healthcare Bios-
ciences, USA; ECL-Antirabbit IgG–Horseradish #45000682, Fisher Heal-
thCare, USA) prepared in 5% milk in TBS-T at 1:5000 dilution . Image J 
(National Institutes of Health, USA) was used to analyze and quantify im-
munoreactive bands of target proteins .
Statistical Analysis
Data were expressed as mean ± SEM, unless otherwise specified . Com-
parison of several means was performed using one-way (infarct size) or 
two-way (hemodynamics) ANOVA, when appropriate, and the post hoc 
test used was the Newman–Keuls test . Hemodynamic data were analy-
zed with repeated measures . Changes in gene expression, gene product, 
and NO were analyzed using mixed-effects modeling with a random effect 
accounting for within-day or within-blot correlation, and treatment group 
and measurement time as crossed fixed effects. For significance testing, 
only the preplanned pairwise comparisons of the two treatment groups for 
each time point and the comparison of each time point to baseline within 
both treatment groups were considered . The familywise type I error rate 
was controlled at 5% for each location using the single-step adjustment 
method based on the multivariate normal distribution .8 Sample size was 
selected based on the previous experience of the known biological varia-
bility within the model . All tests were two tailed, and analyses were per-
formed using 2.12.0 (R Foundation for Statistical Computing, Austria) with 
the nlme 3 .1–97 and multcomp 1 .2–4 packages .
Results
Systemic Hemodynamics
Twenty-four animals were instrumented to obtain 24 successful infarct 
size experiments . There were no significant differences in hemodynami-
cs between experimental groups at baseline (table 2) . Isoflurane caused 
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similar decreases (P < 0 .05) in heart rate, mean arterial pressure, and rate 
pressure product in the presence or absence of DAHP . Hemodynamics 
returned to baseline values after discontinuation of the anesthetic . DAHP 
alone produced slight decreases in mean arterial pressure before coronary 
artery occlusion, although there were no differences in hemodynamics 
between groups during coronary artery occlusion and reperfusion .
Table 2.  Hemodynamics
Reperfusion (h)
Baseline Isoflurane Preocclusion 30-min 
OCC
1 2
HR (beats × min−1)
CON 323 ± 27 — 315 ± 21 342 ± 35 331 ± 36 325 ± 29
APC 371 ± 63 293 ± 82* 339 ± 54 371 ± 64 363 ± 46 363 ± 41
DAHP 348 ± 32 — 353 ± 44 360 ± 42 342 ± 47 333 ± 42
DAHP + APC 368 ± 40 293 ± 24* 363 ± 37 370 ± 35 359 ± 21 354 ± 14
MAP (mmHg)
CON 112 ± 17 — 115 ± 12 123 ± 16 103 ± 20 97 ± 16*
APC 118 ± 13 68 ± 14* 108 ± 9 114 ± 4 88 ± 16* 87 ± 10*
DAHP 117 ± 26 — 101 ± 20* 100 ± 21* 82 ± 10* 81 ± 16*
DAHP + APC 118 ± 21 68 ± 11* 100 ± 15* 107 ± 16 89 ± 14* 80 ± 7*
RPP (beats × min−1 × mmHg × 103)
CON 44 .4 ± 8 .2 — 44 .6 ± 5 .3 48 .1 ± 10 .9 40 .8 ± 11 .1 38 .3 ± 8 .2
APC 51 .5 ± 12 .8 27 .4 ± 11 .7* 44 .4 ± 8 .9* 48 .4 ± 7 .9 38 .6 ± 6 .0* 39 .2 ± 7 .1*
DAHP 47 .9 ± 6 .1 — 46 .7 ± 10 .7 45 .2 ± 10 .5 40 .2 ± 9 .9* 36 .6 ± 8 .2*
DAHP + APC 53 .5 ± 11 .6 28 .1 ± 4 .8* 48 .6 ± 8 .8 48 .3 ± 10 .8 41 .4 ± 6 .7* 37 .9 ± 3 .4*
Data are mean ± SD.
*Significantly (P < 0.05) different from baseline.
APC = anesthetic preconditioning; CON = control; DAHP = 2,4-diamino-6-hydroxpyrimi-
dine; HR = heart rate; MAP = mean arterial blood pressure; OCC = coronary artery occlu-
sion; RPP = rate pressure product.
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Inhibition of GTPCH-1 Abolished APC
The AAR expressed as a percentage of LV weight was similar among gro-
ups (control, 40 ± 1; APC, 38 ± 3; DAHP, 39 ± 2; and APC + DAHP, 41 ± 2%) . 
APC significantly (P < 0 .05) decreased myocardial infarct size (fig . 2: 
43 ± 2% of AAR; n = 6) compared with control experiments (57 ± 1%; n = 
6) . DAHP alone had no effect on infarct size (57 ± 1%; n = 6), but comple-
tely abolished the protection afforded by APC (60 ± 2%; n = 6) .
Fig. 2.  Myocardial infarct size depicted as a percentage of the area at risk for 
infarction in CON rats and rats subjected to APC in the absence or presence of 
DAHP . 
Data are expressed as mean ± SE. *P < 0.05 versus control; †P < 0.05 versus APC alone. 
APC = anesthetic preconditioning; CON = control; DAHP = 2,4-diamino-6-hydroxypyrimi-
dine.
APC Produced Time-dependent Increases  
in Myocardial NO after Ischemia and Reperfusion
There were no differences in production of NO−2 or NOx before coronary 
artery occlusion in control (158 ± 16 [n = 4] and 1,010 ± 58 pmol/mg protein 
[n = 4]) or APC groups (150 ± 13 [n = 4] and 909 ± 47 [n = 3]), respectively . 
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NO production (figs . 3 and 4) was unchanged by coronary artery occlusion 
in either group . In the APC group, NO−2 was significantly (P < 0 .05) increa-
sed after 60 (1 .5 ± 0 .1 fold [n = 4]) and 90 min of reperfusion (1 .4 ± 0 .1 fold 
[n = 4]) . NO−2 and NOx production was significantly higher in the APC gro-
up after reperfusion, whereas NOx production was decreased after reper-
fusion (0 .3 ± 0 .1 fold [n = 5] and 0 .3 ± 0 .1 fold [n = 5], respectively) in con-
trol experiments . DAHP pretreatment decreased NO production (NO−2 and 
NOx, respectively) to a similar extent in both groups before coronary artery 
occlusion (control: 73 ± 6 [n = 4] and 221 ± 25 [n = 3]; and APC: 73 ± 4 [n = 
4] and 175 ± 31 pmol/mg protein [n = 3]), and inhibition of GTPCH-1 aboli-
shed increases in NO production by APC during reperfusion .
Fig. 3.  Time-dependent changes in NO−2 production in control rats and in rats 
subjected to APC with or without DAHP, before (PreOcc) and during Occ, and after 
reperfusion (60 and 90 min) . 
Data are expressed as mean ± SE. *P < 0.05 versus PreOcc baseline; †P < 0.05 versus 
control at the same time point;‡P < 0.05 versus respective control without DAHP. APC = an-
esthetic preconditioning; DAHP = 2,4-diamino-6-hydroxypyrimidine; Occ = coronary artery 
occlusion; PreOcc = before Occ.
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APC Favorably Modulated GTPCH-1 and eNOS Expression 
after Myocardial Ischemia and Reperfusion
GTPCH-1 mRNA abundance (fig . 5, A and B) was unchanged by coro-
nary artery occlusion compared with baseline; however, gene expression 
was significantly (P < 0 .05) increased after 60 min of reperfusion in both 
the control (3 .5 ± 1 .1 fold [n = 4]) and APC (11 .0 ± 3 .6 fold [n = 4]) groups . 
In contrast, eNOS gene expression (fig . 5, C and D) was substantially 
down-regulated in control animals (n = 4) during coronary artery occlu-
sion and after 60 and 90 min of reperfusion; and this effect was mitigated 
by APC (n = 4) . In the APC group, eNOS expression returned to baseline 
values at 60 min of reperfusion and was significantly greater than that ob-
served in control experiments .





production in control rats and in rats subjected to APC with or without DAHP, be-
fore (PreOcc) and during Occ, and after reperfusion (60 and 90 min) . 
Data are expressed as mean ± SE. *P < 0.05 versus PreOcc baseline;
†P < 0.05 versus control at the same time point; ‡P < 0.05 versus respective control without 
DAHP. APC = anesthetic preconditioning; DAHP = 2,4-diamino-6-hydroxypyrimidine; Occ = 
coronary artery occlusion; PreOcc = before Occ.
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GTPCH-1 and eNOS protein were unchanged by coronary artery occlusion 
(fig . 6) in control or APC groups . However, APC increased both GTPCH-1 
and eNOS protein expression (by 1 .3 ± 0 .3 [n = 5] and 1 .3 ± 0 .2 arbitrary 
units [n = 5], respectively) at 60 min of reperfusion, and this increase was 
significantly greater than that observed in control experiments . Increases 
in eNOS expression were also sustained after 90 min of reperfusion in the 
APC group (n = 5) .
Fig. 5.  Time-dependent changes in GTPCH-1 (A) and eNOS (B) gene expression 
in CON (A, B) rats and in rats subjected to APC (C, D), before (PreOcc) and during 
Occ, and after reperfusion (30, 60, and 90 min) . 
Data are expressed as mean ± SE. *P < 0.05 versus PreOcc baseline; †P < 0.05 versus 
control at the same time point. APC = anesthetic preconditioning; CON = control; eNOS = 
endothelial nitric oxide synthase; GTPCH-1 = guanosine triphosphate cyclohydrolase; Occ 
= coronary artery occlusion; PreOcc = before Occ.
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Fig. 6.  Time-dependent changes in GTPCH-1 (A) and eNOS (B) protein expression 
in CON rats and in rats subjected to APC, before PreOcc and during Occ, and after 
reperfusion (60 and 90 min) . 
Representative western blots are shown above the summary data. Data are expressed as 
mean ± SE. *P < 0.05 versus PreOcc baseline; †P < 0.05 versus control at the same time 
point. APC = anesthetic preconditioning; CON = control; eNOS = endothelial nitric oxide 
synthase; GTPCH-1 = guanosine triphosphate cyclohydrolase; Occ = coronary artery occlu-
sion; PreOcc = before Occ
Discussion
The results of this investigation demonstrated that isoflurane administe-
red before ischemia effectively reduced myocardial ischemia and reper-
fusion injury by a GTPCH-1–dependent mechanism .  APC increased the 
expression of GTPCH-1 and eNOS and stimulated the production of NO in 
myocardium after reperfusion .  The cardioprotective effects of APC were 
blocked by DAHP, a pharmacologic antagonist of GTPCH-1, and this in-
hibitor also abolished APC-induced increases in NO .  Taken together with 
previous evidence, the findings suggest that isoflurane stimulates a NO 
biosynthetic pathway, and this action represents an important mechanism 
contributing to the cardioprotective effects of volatile anesthetics .
eNOS-derived NO has been repeatedly implicated as a central mediator 
of anesthetic cardioprotection .1,4,9–11  We have previously demonstrated 
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that isoflurane increased the production of NO by human coronary artery 
endothelial cells in vitro,12 and this effect was dependent on interactions 
between eNOS and its physiologic binding partner, heat shock protein 90 .1 
Isoflurane enhanced the association between heat shock protein 90 and 
eNOS and increased the phosphorylation (activation) of eNOS at serine 
1177 .1,11,12  In contrast to these favorable effects, nonselective NOS anta-
gonists, specific inhibitors of heat shock protein 90,1 and hyperglycemia2 
all abolished anesthetic-induced reductions of myocardial infarct size in 
experimental models .  Interestingly, hyperglycemia decreased isoflura-
ne-stimulated colocalization of heat shock protein 90 with eNOS, the ratio 
of phosphorylation to total eNOS, and NO production in endothelial cells, 
and the findings suggested that modulation of a NO biosynthetic pat-
hway may play a critical role in the pathogenesis of myocardial ischemia 
and reperfusion injury .  This contention was corroborated by the findin-
gs that isoflurane-stimulated endothelial cells protected cardiomyocytes 
in co-culture against hypoxia and reoxygenation injury (decreased lacta-
te dehydrogenase release and delayed opening of the mitochondrial per-
meability transition pore) .  Interestingly, the beneficial paracrine effects of 
endothelial cells on cardiomyocytes were NO dependent and blocked by 
NOS inhibition12 or by culturing endothelial cells, but not cardiomyocytes, 
in high glucose media .13
The deleterious effects of myocardial ischemia on eNOS activity have 
been reported previously .14  However, the present results extend these 
observations . eNOS gene expression was markedly decreased after co-
ronary artery occlusion and reperfusion, but this action was mitigated by 
APC . APC increased eNOS protein during reperfusion accounting, in part, 
for increased NO production in myocardium of animals subjected to APC . 
In addition, isoflurane enhanced the compartmentalization of eNOS within 
endothelial caveolae, an action that increased serine 1177 phosphorylati-
on and NO production . 11  Thus, the regulation of NO production by ane-
sthetics is complex and mediated by interactions with numerous proteins 
involved in NO biosynthesis .
eNOS activity is regulated by its cofactor BH4, a pteridine, that is synthe-
sized de novo by GTPCH-1, the first and rate limiting step in this synthetic 
pathway .15  GTPCH-1 is constitutively expressed in cardiomyocytes, coro-
nary vascular endothelial cells, and vascular smooth muscle cells,16–18 and 
the expression of this NO biosynthetic pathway protein is also inducible 
by oxidative stress .15 The current findings demonstrated that GTPCH-1 
mRNA was increased at 60 min of reperfusion in both control myocardi-
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um and animals subjected to APC .  However, APC significantly increa-
sed GTPCH-1 protein at 60 min of reperfusion, whereas the expression 
of GTPCH-1 was unchanged in control experiments . These findings sug-
gested that the cardioprotective effects of isoflurane were dependent on 
GTPCH-1 and regulation of eNOS during reperfusion, because infarct size 
reduction and enhanced NO production during APC were abolished by an 
inhibitor of GTPCH-1 .  The findings confirm and extend previous evidence 
that targeted overexpression of GTPCH-1 in endothelial cells13 or myo-
cardium19 protects against ischemia and reperfusion injury in vivo and in 
vitro .  GTPCH-1 expression and NO production were increased in Brown 
Norway rats that are resistant to myocardial infarction compared with the 
ischemia-sensitive Dahl S rats, 20 and human genetic variants of GTPCH-1 
may predict cardiovascular risk .21 Thus, modulation of GTPCH-1 may be 
adaptive against myocardial injury .
Isoflurane has been previously shown to increase the ratio of reduced 
(BH4) to oxidized (BH2) biopterin2 in endothelial cells, concomitantly with 
increased NO production .  In contrast, hyperglycemia produced deleterio-
us effects on BH4 and a loss of cardioprotection during APC in vivo .  Con-
versely, increased BH4 content by administration of a metabolic precursor, 
sepiapterin, restored the protective effects of APC to reduce myocardial 
infarct size2 and reestablished protective endothelial cell–cardiomyocyte 
interactions during hyperglycemia .13 Overexpression of human GTPCH-1 
gene profoundly increased BH4 content in myocardium of transgenic mice 
and restored the protective effects of ischemic preconditioning during 
hyperglycemia .19 During preliminary experiments, BH4 concentrations in 
reperfused rat myocardium were below the limits of detection, a finding 
consistent with previous reports that BH4 levels were depleted in ischemic 
hearts .14 Although we were able to detect BH4 in transgenic mouse hear-
ts19 and endothelial cells,2 these measurements were made in the absence 
of prolonged coronary artery occlusion and reperfusion as performed in 
the current investigation .
eNOS generates NO under normal conditions, but it is capable of produ-
cing superoxide anion when electron transfer within the enzyme’s active 
site becomes uncoupled from l-arginine oxidation .22 Uncoupling of eNOS 
occurs in the presence of low concentrations of intracellular BH4 . In con-
trast, isoflurane has been previously demonstrated to increase eNOS di-
merization, 11 an index of “coupled” enzyme activity . Taken together, the 
current and previous findings indicated that APC protects ischemic myo-
42
cardium against injury through important actions to maintain NO biosynt-
hesis by
1. increasing eNOS and GTPCH-1 protein expression and 
2. maintaining eNOS in a coupled state through cofactor (BH4) availabili-
ty, eNOS compartmentalization in caveolae, and enhanced chaperone 
function (heat shock protein 90) . 
Diabetes, hyperglycemia, and other disease states have been shown to 
decrease the bioavailability of NO and contributed to increased cardio-
vascular risk .23,24 Our findings confirmed the central role of NO during 
myocardial ischemia and reperfusion injury and suggested that isoflura-
ne favorably modulated NO biosynthesis . However, the clinical benefits of 
volatile anesthetics have been incompletely realized, in part, because of 
interactions among pharmacologic therapies and disease states that di-
fferentially impact cardio-protective signaling pathways. For example, we 
have demonstrated that APC is blocked by diabetes and hyperglycemia,2 
but the beneficial effects of APC can be restored by statins,25 sepiapterin,2 
overexpression of GTPCH-1,19 and apoliporotein A-1 mimetic,11 and all 
these interventions seem to be dependent on modulation of NO . Although 
as yet unproven in patients, the current and previous findings may support 
the use of a multimodal approach to target NO as a means of decreasing 
cardiovascular risk .24
The current findings should be interpreted within the constraints of seve-
ral potential limitations . Isoflurane produced brief hemodynamic effects, 
although there were no differences in hemodynamics between groups du-
ring coronary artery occlusion and reperfusion that could account for the 
observed results . However, myocardial oxygen consumption was not di-
rectly measured .  The activity of eNOS was assessed by determining the 




3) as indices 
of bioavailable NO, and hence, coupled eNOS activity . NO is converted to 
NO−2, which is further oxidized to NO
−
3 .  Both analyses were performed 
because high background concentrations of NO−3 , combined with a long 
half-life in comparison with NO−2 , may reduce the sensitivity of NOx as a 
sole indicator of eNOS activity .26  The current results suggested that iso-
flurane may have enhanced coupled activity of eNOS; however, we did 
not assess this action in myocardium directly .  Previous evidence indica-
ted that volatile anesthetics increased coupled eNOS activity in endothe-
lial cells 11 and decreased production of reactive oxygen species in myo-
cardium after reperfusion injury . 27  Multiple enzymatic sources of reactive 
43
oxygen species are present in myocardium such as the mitochondrial ele-
ctron transport chain, in addition to uncoupled eNOS, and thus, the preci-
se contributions of different enzymes to the redox balance in myocardium 
may be difficult to identify .
In conclusion, the results of this investigation demonstrated that APC en-
hanced gene and protein expression of an NO biosynthetic pathway that 
includes eNOS and GTPCH-1 .  Activation of this pathway by volatile ane-
sthetics resulted in protection against myocardial infarction and may be a 
major determinant of sensitivity versus resistance to myocardial ischemia 
and reperfusion injury .
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